Content
All content, including text, graphics, images and information etc., contained in or available through this literature is for general information purposes only. For diagnosis or treatment of any medical condition, please consult your physician/doctor. Becton Dickinson India Private Limited and or its affiliates, its employees are not liable for any damages/claims to any person in any manner whatsoever. 1913 BD merged with Oscar O.R. Schwidetzky’s surgical import company, bringing his Asepto™ bulb syringe along with helping to develop the American-made ACE® bandage. 1981 A new plant is built in Plymouth, England to manufacture BD Vacutainer® system products and serve a growing European market.
Impact lives and your career
A bloodstream infection (BSI) can lead to a dysregulated immune response if untreated. To make substantial improvements to BSI testing, consider the entire diagnostic pathway – from blood culture collection to result. It has advanced fluorescence detection technology, exceptional media performance and instrument reliability—adding vial-activated workflow, advanced ergonomics, blood culture observation and customer-focused data management. The easy-to-use workflow comes in a compact, modular design, which can be adapted to multiple space- and time-saving configurations for your laboratory staff. From collecting specimens to reporting results, the diagnostic pathway has multiple points, each with the potential to optimize efficiencies and advance the quality of patient care. BD offers a comprehensive portfolio of integrated solutions designed to help your facility elevate the patient experience and position your lab as a vital resource, rather than a necessary cost center.
Investors
1956 BD enters the Brazilian syringe market and quickly becomes the largest provider in the country with two modern plants and HQ in Sao Paulo.
BD Integrated Diagnostic Solutions
The BD COR™ System uses multiplex PCR assay design and requires less Betinwin than 1 hour of daily hands-on time for the full BD COR™ system workflow and only 2 interactions. In connection with today’s announcement, the company has decided to postpone its Investor Day, previously scheduled for February 26, 2025, to allow BD to focus on the transaction. The company expects to provide a comprehensive update on strategy and outlook in the future closer to the separation. BD’s board of directors is committed to exploring all opportunities to execute the separation in a manner that maximizes shareholder value, including possible options such as a Reverse Morris Trust, sale, spin-off or other transaction.
1987 BD built a plant to manufacture diagnostic products in Fukushima, Japan. 2022 BD becomes the first company to combine flow cytometry with fluorescence imaging and image-based decisioning to sort individual cells based on visual details of the cell at exceptionally high speed (15,000 cells per second). 1 Reflects comparable FY24 revenue, adjusted for a full year of Advanced Patient Monitoring revenue generated during Edwards Lifesciences’ ownership. Please be aware of potentially fraudulent job postings on other websites or suspicious recruiting email or text messages that attempt to collect your confidential information.
BD Medical
The BD MAX™ system offers you an efficient path to improved clinical outcomes by combining and automating extraction and thermocycling into a single platform capable of running both FDA-cleared and open system assays. Flexibility and standardization allow you to address the breadth of your testing needs. Please note, not all products, services or features of products and services may be available in your local area.